---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015622"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:38:07.076987+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ArriVent reports Q3 2024 cash of $282.9M, net loss $59.9M; firmonertinib clinical progress highlighted

## Summary
- Cash and cash equivalents $282.9M as of Sept 30, 2024; expected to fund operations into 2026.
- Net loss $59.9M for nine months ended Sept 30, 2024; R&D expenses $58.9M, G&A $11.8M.
- Positive interim firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC 2024 with CNS activity.
- Phase 3 FURVENT trial top-line data for firmonertinib in EGFR exon 20 NSCLC expected in 2025.
- Dose expansion for firmonertinib plus SHP2 inhibitor expected in Q4 2024; ADC candidate selection by early 2025.

## SEC filing metadata
- accession: 0001558370-24-015622
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/0001558370-24-015622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/avbp-20241114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015622
- JSON: https://secwatch.observer/filing/0001558370-24-015622.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.